BCL2 and acute myeloid leukemia: As discussed in this review, targeting the apoptosis pathway by inhibiting Bcl-2 family proteins with venetoclax combined with established chemotherapy is a promising strategy in AML treatment in terms of improving the survival and minimizing the treatment-related toxicity of the AYA age group [23,26,32,64].